Heparin induced thrombocytopenia: Diagnosis and management update

Postgraduate Medical Journal

Volumn 83, Issue 983, 2007, Pages 575-582

  Ahmed, I ^a   Majeed, A ^b   Powell, R ^c  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b WORCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^c LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; COUMARIN; DANAPAROID; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PROSTACYCLIN DERIVATIVE; PROTAMINE SULFATE; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLOOD CLOT LYSIS; CARDIOVASCULAR SURGERY; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GANGRENE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABORATORY TEST; LIVER INJURY; LOW DRUG DOSE; MORBIDITY; PATIENT INFORMATION; PERCUTANEOUS CORONARY INTERVENTION; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SKIN NECROSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT CONTRAINDICATION; VEIN THROMBOSIS; VENOUS LIMB GANGRENE;

ANTICOAGULANTS; CARDIOVASCULAR SURGICAL PROCEDURES; CHONDROITIN SULFATES; DERMATAN SULFATE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HEPARITIN SULFATE; HIRUDINS; HUMANS; PIPECOLIC ACIDS; RECOMBINANT PROTEINS; RENAL DIALYSIS; THROMBOCYTOPENIA; WARFARIN;

EID: 34548723458     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2007.059188     Document Type: Review

References (53)

1. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003;1:1471-8.
2. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 2000;12(suppl F):14F-19F.
3. Strauss R, Wehler M, Mehler K, et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002;30:1765-71.
4. Franchini M. Heparin induced thrombocytopenia: an update. Thrombosis Journal 2005;3:14-20.
5. Rice L. Heparin-induced thrombocytopenia: myths and misconceptions. Arch Intern Med 2004;164:1961-4.
6. Katzung BG. Basic and clinical pharmacology, 9th ed. McGraw Hill, 2004:545-9.
7. Reilly RF. The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin Dial 2003;16:54-60.
8. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995;73:21-8.
9. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-9.
10. Denomme GA, Warkentin TE, Horsewood P, et al. J Lab Clin Med 1997;130:278-84.
11. Carlsson LE, Lubenow N, Blumentritt C, et al. Pharmacogenetics 2003;13:253-8.
12. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
13. Kelton JG: Heparin-induced thrombocytopenia: an overview. Blood Rev 2002;16:77-80.
14. Nand S, Wong W, Yuen B, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997;56:12-16.
15. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. Chest 2004;126:311S-37S.
16. Warkentin TE, Sheppard JI, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8.
17. Andreescu AC, Possidente C, Hsieh M, et al. Evaluation of a pharmacy-based surveillance program for heparin-induced thrombocytopenia. Pharmacotherapy 2002;20:974-80.
18. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 1999;82:439-47.
19. Lubenow N, Kempf R, Eichner A, et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002;122:37-42.
20. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001;135:502-6.
21. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005;111:2671-83.
22. Meyer-Lindenberg A, Quenzel EM, Bierhoff E, et al. Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia. Eur Neuro 1997;37:191-2.
23. Boshkov LK, Warkentin TE, Hayward CP, et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993;84:322-8.
24. Kelton JG, Hursting MJ, Lewis BE. The predictors of clinical outcome in patients with heparin-induced thrombocytopenia. J Thromb Haemost 2003;1(suppl):OC020, [abstract].
25. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 2004;76:240-4.
26. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004;32:976-80.
27. Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology (American Society of Hematology Education Program) 2003:497-519.
28. Francis J, Drexler A. Frequency of heparin-platelet factor 4 antibodies in patients presenting to the emergency room with symptoms of thrombosis. J Thomb Haemost 2003;1(suppl 1):P1147, [abstract].
29. Keeling D, Davidson S, Watson H. Guideline: the management of heparin-induced thrombocytopenia. Br J Haematol 2006;133:259-69.
30. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51.
31. Klein HG, Bell WR. Disseminated intravascular coagulation during heparin therapy. Ann Intern Med 1974;80:477-81.
32. Keeling DM, Richards EM, Baglin TP. Platelet aggregation in response to four low molecular weight heparins and the heparinoia ORG 10172 in patients with heparin-induced thrombocytopenia. Br J Haematol 1994;86:425-6.
33. Chong BH, Gallus AS, Cade JF, for the Australian HIT Study Group. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost 2001;86:1170-5.
34. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51.
35. Lewis BE, Wallis DE, Berkowitz SD, for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43.
36. Lubenow N, Eichler P, Lietz T, et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of three prospective studies. Blood 2004;104:3072-7.
37. Vanholder R, Camez A, Veys N, et al. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 1997;77:650-5.
38. Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT and clinical relevance. Blood 2000;96:2373-8.
39. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108:2062-5.
40. Chong BH, Magnani HN. Danaparoid for the treatment of heparin-induced thrombocytopenia: an overview. In: Warketin TE, Greinacher A, eds. Heparin-induced thrombocytopenia, 3rd ed. New York: Marcel Dekker, 2004:371-96.
41. Keng TB, Chong BH. Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. Br J Haematol 2001;114:394-396.
42. Kodityal S, Manhas AH, Udden M, et al. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures. Eur J Haematol 2003;71:109-113.
43. Farner B, Eichler P, Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001;85:950-7.
44. Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cath Cardiovasc Interv 2002;57:177-84.
45. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29.
46. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993;69:157-63.
47. Fischer KG. Hirudin in renal insufficiency. Semin Thromb Hemost 2002;28:467-82.
48. Murray PM, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during in end-stage renal disease. Kidney Int 2004;66:2446-53.
49. Bradner J, Hallisey RK, Kuter DJ. Fondaparinux in the treatment of heparin-induced thrombocytopenia. Blood 2004;104:492a.
50. Pinto DS, Sperling RT, Tu RM, et al. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cath Cardiovasc Interv 2003;58:65-8.
51. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004;121:593-99.
52. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-9.
53. Alsoufi B, Boshkov LK, Kirby A, et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality. Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual 2004;7:155-71.